Risk reduction by preventing stroke: Need for blockade of angiotensin II and catecholamines?

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 5, 2007, Pages

  Rupp, Heinz ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiotensin II receptor blocker (ARB); Blood pressure; Eprosartan; Morbidity and Mortality after Stroke (MOSES) study; Noradrenaline; Stroke; Valsartan Antihypertensive Long term Use Evaluation (VALUE) trial

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CATECHOLAMINE; CHYMASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NITRENDIPINE; NORADRENALIN; SUNC 8257; UNCLASSIFIED DRUG; VALSARTAN; ZD 7155;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; NORADRENALIN RELEASE; RISK REDUCTION; STROKE;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CATECHOLAMINES; HUMANS; HYPERTENSION; IMIDAZOLES; NOREPINEPHRINE; STROKE; TETRAZOLES; THIOPHENES; VALINE;

EID: 37849043894     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X260737     Document Type: Conference Paper

References (17)

1. McDonald JE, Padmanabhan N, Petrie MC, et al. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans. Circulation 2001;104:1805-8
2. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003;107:2555-8
3. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000;36:638-41
4. Hill CE, Hirst GD, Silverberg GD, et al. Sympathetic innervation and excitability of arterioles originating from the rat middle cerebral artery. J Physiol 1986;371:305-16
5. Boehm S, Kubista H. Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 2002;54:43-99
6. Pinheiro H, Moura D, bino-Teixeira A, et al. A comparison of AT1 angiotensin II antagonists at pre- and postjunctional angiotensin II receptors of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol 2002;366:537-42
7. Guimaraes S, Carneiro C, Brandao F, et al. A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta. Naunyn Schmiedebergs Arch Pharmacol 2004;370:262-9
8. Rupp H, Benkel M, Maisch B. Control of cardiomyocyte gene expression as drug target. Mol Cell Biochem 2000;212:135-42
9. Ohlstein EH, Brooks DP, Feuerstein GZ, et al. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244-51
10. Arosio E, De MS, Prior M, et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 2005;23:1923-7
11. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
12. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
13. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26
14. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64
15. Rabbia F, Martini G, Cat Genova G, et al. Antihypertensive drugs and sympathetic nervous system. Clin Exp Hypertens 2001;23:101-11
16. Pinheiro H, Moura D, Albino-Teixeira A, et al. A comparison of AT1 angiotensin II antagonists at pre- and postjunctional angiotensin II receptors of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol 2002;366:537-42
17. de la Sierra A, Munoz A, Arcos E, et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl 2004;2:5-10